What is TROP2?
What is TROP2?
Trop2 is a transmembrane glycoprotein encoded by the Tacstd2 gene. It is an intracellular calcium signal transducer that is differentially expressed in many cancers. It signals cells for self-renewal, proliferation, invasion, and survival. It has stem cell-like qualities.
Where is Trop 2 expressed?
Trop2 is expressed in normal human tissues, including breast, cervix, kidney, lung and pancreas, and is upregulated in all cancers, regardless of baseline Trop2 expression.
What is TROP2 ADC?
The monoclonal antibody used in DS-1062 is a humanised anti-TROP2, a cell-surface glycoprotein. “TROP2 is overexpressed in many cancers including up to 80% of triple negative breast cancers,” Gallant says. “High TROP2 expression has also been identified in a majority of patients with NSCLC.
Is Trop2 a biomarker?
Trop-2 Overexpression as a Valuable Biomarker in Solid Tumors. Trop-2 is inextricably linked to cancer progression and metastasis because of its role as a key regulator of the hallmarks of cancer, including cell growth, proliferation, migration, invasion, and survival.
Is Trodelvy a ADC?
TRODELVY is a type of drug called an antibody-drug conjugate, or ADC for short. Unlike traditional chemotherapy, ADCs contain 3 parts: an antibody, an anti-cancer drug, and a linker.
Who makes Trodelvy?
A year after granting accelerated approval to Trodelvy (sacituzumab govitecan-hziy), the FDA has granted to full approval to the antibody–drug conjugate as a treatment for triple-negative breast cancer, according to its maker, Gilead Sciences.
Who makes Sacituzumab Govitecan?
Credit: Gilead Sciences, Inc. Among participants without brain metastases, sacituzumab measurably shrank tumors in 35% of those who received it, according to trial results published April 22 in the New England Journal of Medicine.
Is Avastin a PARP inhibitor?
Avastin is an anti-angiogenic drug that interferes with the development of blood vessels that tumors need to thrive. Lynparza is a PARP inhibitor, which can be lethal to cancer cells by hindering their ability to repair their damaged DNA.
What does Trodelvy treat?
Trodelvy (chemical name: sacituzumab govitecan-hziy) is approved to treat adults diagnosed with unresectable locally advanced or metastatic triple-negative breast cancer who have received two or more systemic therapies, at least one of which was for advanced-stage disease.
Is Trodelvy an immunotherapy?
Trodelvy is an immune targeted therapy medicine. It is made up of: sacituzumab, a type of molecule called a monoclonal antibody, that targets the Trop-2 protein; the Trop-2 protein is found in more than 90% of triple-negative breast cancers.
